Canaccord Genuity analyst William Plovanic maintained a Buy rating on Staar Surgical Company (NASDAQ:STAA) on Sunday, setting a price target of $84, which is approximately 0.44% below the present share price of $84.37.
Plovanic expects Staar Surgical Company to post earnings per share (EPS) of $0.08 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Staar Surgical Company, with an average price target of $84.33.
The analysts price targets range from a high of $100 to a low of $69.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $47.08 million and a net profit of $4.88 million. The company's market cap is $3.89 billion.
According to TipRanks.com, Canaccord Genuity analyst William Plovanic is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.6% and a 53.36% success rate.
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.